AtriCure, Inc. filings document financial results, governance matters and capital arrangements for a Nasdaq-listed medical technology company focused on Afib, left atrial appendage management and post-operative pain management. Form 8-K reports furnish quarterly and annual results, amended financial guidance disclosures, product-revenue drivers and material definitive agreements, including an asset-based revolving credit facility involving AtriCure, LLC as a borrower.
Proxy filings cover board and shareholder voting matters, executive compensation, equity awards and related governance disclosures. The filings also identify AtriCure common stock as registered on the Nasdaq Global Market under the symbol ATRC.
AtriCure, Inc. (ATRC) is the issuer in BlackRock, Inc.'s report of beneficial ownership of 7,837,484 common shares, or 15.4% of the class. BlackRock reports sole voting power over 7,763,851 shares and sole dispositive power over 7,837,484 shares, with 0 shared voting power and 0 shared dispositive power. The report identifies iShares Core S&P Small-Cap ETF as having an interest in more than 5% of AtriCure's total outstanding common stock.
AtriCure, Inc. Chief Technical Officer Salvatore Privitera sold 4,519 shares of common stock at $60 per share on September 23, 2026. The shares were held directly, and Privitera reported 142,745 shares following the sale. The sale was made under a 10b5-1 trading plan adopted on February 20, 2026.
AtriCure, Inc. (ATRC) officer Salvatore Privitera gave notice of a proposed sale of 4,519 common shares, with an aggregate market value of $271,140.00. The approximate sale date is September 23, 2026, through Morgan Stanley Smith Barney LLC. The notice also lists Privitera sales during the prior three months: 3,657 common shares for $201,135.00 on September 8, 2026, and 7,763 common shares for $407,557.50 on September 2, 2026.
AtriCure, Inc. (ATRC) director Regina E. Groves reported selling 5,313 shares of common stock on September 11, 2026 in an open-market or private transaction at a weighted average price of $54.22 per share. The trades were executed between $54.09 and $54.38 per share, leaving her with 34,546 shares held directly. No Rule 10b5-1 trading plan is reported.
AtriCure, Inc. (ATRC) director Regina E. Groves has filed a notice under Rule 144 to sell 5,313 shares of common stock of AtriCure through Fidelity Brokerage Services LLC, with an aggregate market value of $285,095.58 and an approximate sale date of September 10, 2026, on NASDAQ.
The shares are to be sold out of the Groves Family Trust and were acquired as stock awards for compensation on May 25, 2023 (3,564 shares) and May 20, 2022 (1,749 shares). AtriCure reported 50,866,294 shares of this class outstanding in the notice.
AtriCure, Inc. (ATRC) reported that Chief Technical Officer Salvatore Privitera sold 3,657 shares of common stock on September 8, 2026 at a price of $55.00 per share in a sale described as an open market or private transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2026, indicating it was pre-arranged. Following this transaction, Privitera directly holds 147,264 shares of AtriCure common stock.
AtriCure, Inc. (ATRC) is the issuer for which officer Salvatore Privitera has filed a notice of proposed sale of restricted securities under Rule 144. The planned sale covers 3,657 shares of common stock, with the broker listed as Morgan Stanley Smith Barney LLC and an intended sale date of September 8, 2026 on NASDAQ.
The shares to be sold trace to performance shares acquired on February 16, 2021 from the issuer. Over the preceding three months, the same person is reported as having sold 7,763 shares of AtriCure common stock on September 2, 2026 for an aggregate price of $407,557.50.
AtriCure, Inc. (ATRC) reported that Chief Technical Officer Salvatore Privitera sold 7,763 shares of common stock on September 2, 2026 at a price of $52.50 per share in an open-market or private transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2026. After this transaction, he held 150,921 shares of AtriCure common stock directly.
AtriCure, Inc. (ATRC) received a notice that officer Salvatore Privitera intends to sell 7,763 shares of common stock under Rule 144. The shares were acquired from the issuer as restricted stock that vested during the period from March 1, 2020 through March 1, 2021. The proposed sale, through Morgan Stanley Smith Barney’s Executive Financial Services unit, reflects an estimated aggregate market value of $407,557.50 and is associated with trading on NASDAQ.
AtriCure, Inc. (ATRC) reported that Chief Legal Officer Karl S. Dahlquist sold 9,370 shares of common stock on 2026-08-24 in a sale classified as an open market or private transaction. The weighted average sales price was approximately $48.89 per share, with trades executed between $48.88 and $48.89. Following this transaction, Dahlquist directly holds 87,319 AtriCure common shares.